ReviewAnnals of general psychiatry2017
Insulin-like growth factor-1: a possible marker for emotional and cognitive disturbances, and treatment effectiveness in major depressive disorder.
Review in Annals of general psychiatry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- The Insulin-like Growth Factor Family as a Potential Peripheral Biomarker in Psychiatric Disorders: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- The Antidiabetic Metformin as an Adjunct to Antidepressants in Patients with Major Depressive Disorder: A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2020Trial
- A multimodal approach to depression diagnosis: insights from machine learning algorithm development in primary care.European archives of psychiatry and clinical neuroscience · 2026Article
- Role of IGF1/IGFR signaling pathway in neuroprotective effect of Shengmai Dihuang Decoction on CIH-induced cognitive impairment.Journal of traditional and complementary medicine · 2026Article
- Antidepressant and Related Neurobiological and Neurophysiological Effects of Add-On Transcranial Direct Current Stimulation in Major Depressive Disorder with Residual Symptoms: A Randomized, Double-Blind Clinical Trial Protocol.Methods and protocols · 2025Article
- Article
- Protein associations and protein-metabolite interactions with depressive symptoms and the p-factor.Translational psychiatry · 2025Article
- Insulin-like Growth Factor 1 Impact on Alzheimer's Disease: Role in Inflammation, Stress, and Cognition.Current issues in molecular biology · 2025Review
- Effects of an acute maximal exercise bout on serum insulin-like growth factor-1 in adults with MDD.Psychoneuroendocrinology · 2025Article
- Deconstructing depression by machine learning: the POKAL-PSY study.European archives of psychiatry and clinical neuroscience · 2024Article
- Article
- Alterations in anthropometric, inflammatory and mental health parameters during Ramadan intermittent fasting in a group of healthy people: a prospective cohort study.Frontiers in nutrition · 2024Article
- Association between IGF-1 levels and MDD: a case-control and meta-analysis.Frontiers in psychiatry · 2024Article
- Dysregulated zinc homeostasis and microadenomas in the anterior pituitary: pathological insights into suicide risk.Frontiers in psychiatry · 2024Article
- Short-Term Irisin Treatment Enhanced Neurotrophin Expression Differently in the Hippocampus and the Prefrontal Cortex of Young Mice.International journal of molecular sciences · 2023Article
- Prognostic prediction of subjective cognitive decline in major depressive disorder based on immune biomarkers: a prospective observational study.BMC psychiatry · 2023Observational
- Article
- Antidepressant Effect of Intermittent Long-Term Systemic Administration of Irisin in Mice.International journal of molecular sciences · 2022Article
- Targeting Insulin-Like Growth Factor-I in Management of Neurological Disorders.Neurotoxicity research · 2022Review
- Preclinical and clinical evidence of IGF-1 as a prognostic marker and acute intervention with ischemic stroke.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Depression and cognitive dysfunction share a common neuropathological platform. Abnormal neural plasticity in the frontolimbic circuits has been linked to changes in the expression of neurotrophic factors, including IGF-1. These changes may result in clinical abnormalities observed over the course of major depressive disorder (MDD), including cognitive dysfunction. The present review aimed to summarize evidence regarding abnormalities of peripheral IGF-1 in MDD patients and assess a marker and predictive role of the neurotrophin for emotional and cognitive disturbances, and treatment effectiveness. A literature search of the PubMed database was conducted for studies, in which peripheral IGF-1 levels were evaluated. Our analysis revealed four main findings: (1) IGF-1 levels in MDD patients mismatch across the studies, which may arise from various factors, e.g., age, gender, the course of the disease, presence of cognitive impairment, ongoing therapy, or general health conditions; (2) the initial peripheral IGF-1 levels may predict the occurrence of depression in future; (3) peripheral IGF-1 levels may reflect cognitive dysfunction, although the data is limited; (4) it is difficult to evaluate the influence of treatment on IGF-1 levels as there is discrepancy of this growth factor among the studies at baseline, although most of them showed a decrease in IGF-1 levels after treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.